Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Helium-3 MRI reveals hidden airflow secrets in lungs

NCT ID NCT02154568

Knowledge-focused Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study uses a special MRI technique with inhaled helium-3 gas to measure how fast air moves through the windpipe and lungs. Researchers will compare airflow in healthy volunteers and people with COPD or constrictive bronchitis. The goal is to gather real-world data to improve computer models that predict breathing problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperpolarized helium-3 gas
What this could lead to
If successful, this could help doctors better understand and predict airflow problems in lung diseases like COPD, potentially improving diagnosis and treatment planning.
What could go wrong
This is a small, early-stage study focused on measuring airflow, not testing a treatment. The results may not directly lead to new therapies or apply to all patients with lung disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Nov 2013

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy subjects: * Normal PFT values: FEV1 \> 90% predicted; and Forced vital capacity (FVC) \> 90% predicted * Normal chest x-ray (CXR) * Medical history: No active pulmonary symptoms (cough, shortness of breath, sputum); Negative history of pulmonary disease; Negative smoking history (never smoked) * Pulmonary Disease Subjects: * PFT values: FEV1/FVC \< 70% (indicative of obstruction); and 30% \< FEV1 \< 50% predicted * CXR normal except hyperinflation * Symptoms - chronic shortness of breath * All test subjects, healthy and with COPD should have similar physical anthropometric characteristics: * Similar age with age difference less than 3 years * Similar height (within 3-4 inches) Exclusion Criteria: * Any condition for which a MRI procedure is contraindicated. * Presence of any non-MRI compatible metallic material in the body, such as pacemakers, metallic clips, etc. * Likelihood of claustrophobia * Chest circumference greater than that of the helium MR coil. * Pregnancy, by report of subject. Clinically in the Department of radiology at UVA, self report is used when screening patients for MR scans as well as CT scans and fluoroscopy studies. If the subject reports there is any chance of their being pregnant a urine pregnancy test will be performed prior to any imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Constrictive bronchitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchiolitis obliterans syndrome chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Constrictive bronchitis COPD Healthy

Contacts and locations

Locations

  • Snyder Translation Fontaine Research Center 480 Ray C. Hunt Drive

    Charlottesville, Virginia, 22908, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.